# Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Study · id `cardio:ct-nct04847232` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04847232](<https://clinicaltrials.gov/study/NCT04847232>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04847232

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 2690 participants.

## Technical summary

Registry record NCT04847232. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-30 (actual); primary completion 2024-03-07 (actual). Results posted on 2025-06-18.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2690 participants (enrolled count; ClinicalTrials.gov record NCT04847232, source copy `cardio:ctgov-nct04847232-2025-06-18`, retrieved 2026-10-26)
- Started: 2021-04-30 (actual) (ClinicalTrials.gov record NCT04847232, source copy `cardio:ctgov-nct04847232-2025-06-18`, retrieved 2026-10-26)
- Primary completion: 2024-03-07 (actual) (ClinicalTrials.gov record NCT04847232, source copy `cardio:ctgov-nct04847232-2025-06-18`, retrieved 2026-10-26)
- Completion: 2024-03-07 (actual) (ClinicalTrials.gov record NCT04847232, source copy `cardio:ctgov-nct04847232-2025-06-18`, retrieved 2026-10-26)
- Results first posted: 2025-06-18 (ClinicalTrials.gov record NCT04847232, source copy `cardio:ctgov-nct04847232-2025-06-18`, retrieved 2026-10-26)
- Countries: United States; Argentina; Austria; Brazil; Bulgaria; Canada; China; Czechia; Germany; Hungary; India; Italy; Japan; Malaysia; Mexico; Peru; Poland; Russia; Slovakia; Spain; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT04847232, source copy `cardio:ctgov-nct04847232-2025-06-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04847232-2025-06-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
- Condition: Hyperkalemia
- Intervention (Drug): Sodium Zirconium Cyclosilicate (SZC)
- Intervention (Drug): SZC Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis (`cardio:pubmed-40618849`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7ade58af97e5ab6d156f9c4913d756f01717fcdc377f22540b1bb236a8b0b57c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
